Treatment and progression of patients in Sweden with metastatic castration-sensitive prostate cancer
DOI:
https://doi.org/10.2340/1651-226X.2026.45110Keywords:
Prostatic neoplasms, castration resistant, Sweden, retrospective studies, disease progressionAbstract
Background and purpose: The metastatic castration-sensitive prostate cancer (mCSPC) treatment landscape in Sweden has evolved in recent years. The purpose of this study is to provide contemporary registry data on outcomes and treatment patterns in a nationwide cohort of Swedish patients with de novo mCSPC.
Patient/material and methods: This retrospective cohort study included patients in Sweden with a clinical diagnosis of de novo mCSPC registered between January 1, 2017 and December 31, 2023. The primary outcome was time from de novo mCSPC diagnosis to mCRPC or death (2017–2023). Secondary outcomes included overall survival (OS), comorbidities, co-medication use, and treatment sequencing. OS, time to progression or death, and treatment sequencing for the 2017–2020 and 2021–2023 time periods were also analyzed.
Results: A total of 2421 patients with de novo mCSPC were included in the primary analysis (mean age: 72.8 years). The median time to progression or death was 22.7 months (95% CI: 21.2–24.1), and the median OS was 49.8 months (95% CI: 47.0–52.6). Median time to progression or death increased from 19.9 months (95% CI: 18.6–21.2) in 2017–2020 to 30.0 months (95% CI: 26.6–33.3) in 2021–2023, while the proportion of patients receiving initial doublet or triplet therapy rose from 42.5 to 68.8%. No differences in OS were observed between different time periods.
Interpretation: In Sweden (2017–2023), increased time to progression or death was observed in patients with de novo mCSPC.
Downloads
References
Force LM, Kocarnik JM, May ML, Bhangdia K, Crist A, Penberthy L, et al. The global, regional, and national burden of cancer, 1990–2013, with forecasts to 2050: a systematic analysis for the Global Burden of Disease Study 2023. Lancet. 2025;406(10512):1565–86. DOI: https://doi.org/10.1016/S0140-6736(25)01635-6
International Agency for Research on Cancer, Association of the Nordic Cancer Registries. NORDCAN countries: prostate cancer factsheet (2018–2022). Lyon: World Health Organization; 2024 [updated 2024 Aug]. [Cited 2025-05-19]. Available from: https://nordcan.iarc.fr/
Zaurito P, Garmo H, Gedeborg R, Ahlberg M, Orrason AW, Styrke J, et al. Prostate cancer incidence in Sweden before, during and after the COVID-19 pandemic. Population-based study. Scand J Urol. 2025;60:93–6. DOI: https://doi.org/10.2340/sju.v60.43172
Storas AH, Tsuruda K, Fossa SD, Andreassen BK. Time trends in systemic treatment for patients with metastatic prostate cancer: a national cohort study. Acta Oncol. 2023;62(12):1716–22. DOI: https://doi.org/10.1080/0284186X.2023.2257876
Stroomberg HV, Helgstrand JT, Brasso K, Larsen SB, Roder A. Epidemiology of men with synchronous metastatic prostate cancer diagnosis – a nationwide 26-year temporal analysis. Eur J Cancer. 2024;213:115110. DOI: https://doi.org/10.1016/j.ejca.2024.115110
Schoen MW, Montgomery RB, Owens L, Khan S, Sanfilippo KM, Etzioni RB. Survival in patients with De Novo metastatic prostate cancer. JAMA Netw Open. 2024;7(3):e241970. DOI: https://doi.org/10.1001/jamanetworkopen.2024.1970
Svensson J, Lissbrant IF, Gauffin O, Hjalm-Eriksson M, Kilany S, Fagerlund K, et al. Time spent in hormone-sensitive and castration-resistant disease states in men with advanced prostate cancer, and its health economic impact: registry-based study in Sweden. Scand J Urol. 2021;55(1):1–8. DOI: https://doi.org/10.1080/21681805.2020.1851762
Corsini C, Garmo H, Orrason AW, Gedeborg R, Stattin P, Westerberg M. Survival trend in individuals with De Novo metastatic prostate cancer after the introduction of doublet therapy. JAMA Netw Open. 2023;6(10):e2336604. DOI: https://doi.org/10.1001/jamanetworkopen.2023.36604
Cazzaniga W, Ventimiglia E, Alfano M, Robinson D, Lissbrant IF, Carlsson S, et al. Mini review on the use of clinical cancer registers for prostate cancer: the National Prostate Cancer Register (NPCR) of Sweden. Front Med (Lausanne). 2019;6:51. DOI: https://doi.org/10.3389/fmed.2019.00051
Van Hemelrijck M, Wigertz A, Sandin F, Garmo H, Hellstrom K, Fransson P, et al. Cohort profile: the National Prostate Cancer Register of Sweden and prostate cancer data base Sweden 2.0. Int J Epidemiol. 2013;42(4):956–67. DOI: https://doi.org/10.1093/ije/dys068
Franck Lissbrant I, Hjalm Eriksson M, Lambe M, Tornblom M, Stattin P. Set-up and preliminary results from the patient-overview prostate cancer. Longitudinal registration of treatment of advanced prostate cancer in the National Prostate Cancer Register of Sweden. Scand J Urol. 2020;54(3):227–34. DOI: https://doi.org/10.1080/21681805.2020.1756402
Kalbfleisch JD, Prentice RL. The statistical analysis of failure time data. 2nd ed. Hoboken, NJ: John Wiley & Sons; 2002. DOI: https://doi.org/10.1002/9781118032985
Ludvigsson JF, Appelros P, Askling J, Byberg L, Carrero JJ, Ekstrom AM, et al. Adaptation of the Charlson comorbidity index for register-based research in Sweden. Clin Epidemiol. 2021;13:21–41. DOI: https://doi.org/10.2147/CLEP.S282475
Westerberg M, Franck Lissbrant I, Damber JE, Robinson D, Garmo H, Stattin P. Temporal changes in survival in men with de novo metastatic prostate cancer: nationwide population-based study. Acta Oncol. 2020;59(1):106–11. DOI: https://doi.org/10.1080/0284186X.2019.1662084
Prostate Cancer Guideline. Regional Cancer Center. Prostate Cancer Care Program: primary treatment of metastatic prostate cancer; version 1.2. 2017 [updated 2025 Nov 12]. Regional Cancer Centres, Stockholm
Sweeney CJ, Chen YH, Carducci M, Liu G, Jarrard DF, Eisenberger M, et al. Chemohormonal therapy in metastatic hormone-sensitive prostate cancer. N Engl J Med. 2015;373(8):737–46. DOI: https://doi.org/10.1056/NEJMoa1503747
James ND, Sydes MR, Clarke NW, Mason MD, Dearnaley DP, Spears MR, et al. Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial. Lancet. 2016;387(10024):1163–77. DOI: https://doi.org/10.1016/S0140-6736(15)01037-5
Fizazi K, Tran N, Fein L, Matsubara N, Rodriguez-Antolin A, Alekseev BY, et al. Abiraterone plus prednisone in metastatic, castration-sensitive prostate cancer. N Engl J Med. 2017;377(4):352–60. DOI: https://doi.org/10.1056/NEJMoa1704174
James ND, de Bono JS, Spears MR, Clarke NW, Mason MD, Dearnaley DP, et al. Abiraterone for prostate cancer not previously treated with hormone therapy. N Engl J Med. 2017;377(4):338–51. DOI: https://doi.org/10.1056/NEJMoa1702900
Fallara G, Lissbrant IF, Styrke J, Montorsi F, Gedeborg R, Sandin F, et al. Rapid ascertainment of uptake of a new indication for abiraterone by use of three nationwide health care registries in Sweden. Acta Oncol. 2021;60(1):56–60. DOI: https://doi.org/10.1080/0284186X.2020.1847321
Bencina G, Petrova E, Sonmez D, Matos Pereira S, Dimitriadis I, Salomonsson S. HTA and reimbursement status of metastatic hormone sensitive prostate cancer, non-metastatic castration-resistant prostate cancer, and metastatic castration-resistant prostate cancer treatments in Europe: a patient access landscape review. J Health Econ Outcomes Res. 2023;10(1):102–10. DOI: https://doi.org/10.36469/001c.75208
Fizazi K, Foulon S, Carles J, Roubaud G, McDermott R, Flechon A, et al. Abiraterone plus prednisone added to androgen deprivation therapy and docetaxel in de novo metastatic castration-sensitive prostate cancer (PEACE-1): a multicentre, open-label, randomised, phase 3 study with a 2 x 2 factorial design. Lancet. 2022;399(10336):1695–707. DOI: https://doi.org/10.1016/S0140-6736(22)00367-1
Smith MR, Hussain M, Saad F, Fizazi K, Sternberg CN, Crawford ED, et al. Darolutamide and survival in metastatic, hormone-sensitive prostate cancer. N Engl J Med. 2022;386(12):1132–42. DOI: https://doi.org/10.1056/NEJMoa2119115
Armstrong AJ, Szmulewitz RZ, Petrylak DP, Holzbeierlein J, Villers A, Azad A, et al. ARCHES: a randomized, phase III study of androgen deprivation therapy with enzalutamide or placebo in men with metastatic hormone-sensitive prostate cancer. J Clin Oncol. 2019;37(32):2974–86. DOI: https://doi.org/10.1200/JCO.19.00799
Chi KN, Chowdhury S, Bjartell A, Chung BH, Pereira de Santana Gomes AJ, Given R, et al. Apalutamide in patients with metastatic castration-sensitive prostate cancer: final survival analysis of the randomized, double-blind, phase III TITAN study. J Clin Oncol. 2021;39(20):2294–303. DOI: https://doi.org/10.1200/JCO.20.03488
Davis ID, Martin AJ, Stockler MR, Begbie S, Chi KN, Chowdhury S, et al. Enzalutamide with standard first-line therapy in metastatic prostate cancer. N Engl J Med. 2019;381(2):121–31. DOI: https://doi.org/10.1056/NEJMoa1903835
Gomez-Veiga F, Szmulewitz RZ, Holzbeierlein J, Azad AA, Iguchi T, Villers A, et al. Clinical outcomes of enzalutamide in metastatic hormone-sensitive prostate cancer in patients aged <75 and ≥75 years: ARCHES post hoc analysis. Eur Urol Oncol. 2024;7(4):860–9. DOI: https://doi.org/10.1016/j.euo.2023.11.012
Liu Y, Zhang HM, Jiang Y, Wen Z, Bao EH, Huang J, et al. Cardiovascular adverse events associated with new-generation androgen receptor pathway inhibitors (ARPI) for prostate cancer: a disproportionality analysis based on the FDA adverse event reporting system (FAERS). Clin Genitourin Cancer. 2023;21(5):594–601.e2. DOI: https://doi.org/10.1016/j.clgc.2023.07.003
Matsukawa A, Yanagisawa T, Parizi MK, Laukhtina E, Klemm J, Fazekas T, et al. Cardiovascular events among men with prostate cancer treated with androgen receptor signaling inhibitors: a systematic review, meta-analysis, and network meta-analysis. Prostate Cancer Prostatic Dis. 2025;28(2):298–308. DOI: https://doi.org/10.1038/s41391-024-00886-0
Merseburger AS, Dornstauder E, Ohlmann CH, Aprikian A, Junker S, Hahn P, et al. Cardiovascular risks and survival with abiraterone vs enzalutamide in chemotherapy-naive metastatic castration-resistant prostate cancer in Germany: AVENGER study. Adv Ther. 2025;42(4):1919–34. DOI: https://doi.org/10.1007/s12325-025-03132-8
Lyon AR, Lopez-Fernandez T, Couch LS, Asteggiano R, Aznar MC, Bergler-Klein J, et al. 2022 ESC guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS). Eur Heart J. 2022;43(41):4229–361. DOI: https://doi.org/10.1093/eurheartj/ehac244
Additional Files
Published
How to Cite
License
Copyright (c) 2026 Johan Styrke, Åsa Jellvert, Marie Hjälm Eriksson, Fredrik Sandin, Elin Axén, Sam Jabbar, Kamilla Juhl Norgaard
This work is licensed under a Creative Commons Attribution 4.0 International License.
